Introduction
Associations of markers of the major histocompatibility complex (MHC)' with type I diabetes mellitus have been amply documented. The incidence of HLA-B8, HLA-B 18, HLA-B 15, HLA-DW3/DR3, and HLA-DW4/DR4 is increased in Caucasian patients with type I diabetes mellitus, while the incidence of HLA-B7 and HLA-DW2/DR2 is decreased (1) (2) (3) (4) (5) (6) (7) (8) . Ofthe other markers encoded within or close to the MHC, the incidence of BF*FJ, a rare allele of the locus for properdin factor B, and C4B*3, an allele of one of the C4 genetic loci, are also increased in insulindependent diabetes mellitus (IDDM) (9, 10) . However, there is no difference between type I diabetic patients and controls in the frequencies of types of glyoxalase I (GLO) (1 1), which is a protein encoded by a genetic locus that is also on the short arm of chromosome 6 but nearer the centromere than the MHC. The genes for the complement proteins factor B (BF), C2 (C2), and C4 (C4A and C4B) are closely linked to one another without known crossovers. The four gene complement haplotypes are inherited as single genetic units which are called complotypes. We previously identified 14 common and distinct complotypes in normal Caucasians (12) and showed that they are closely linked to HLA-DR (13) . HLA-B, DR, and complotype combinations with significant linkage disequilibrium among normal chromosomes were defined as extended haplotypes (14) .
It has been suggested that the markers that confer the highest relative risks for type I diabetes, particularly HLA-DR3 and HLA-DR4, are primary indicators of, or are themselves directly involved in, the initial pathogenesis of pancreatic fl cell destruction (15, 16) . In this view, the other markers at the HLA-B locus (B8, B18, and B15) are secondarily increased because of the known linkage disequilibria in Caucasians of HLA-B8 and B18 with HLA-DR3, and HLA-B15 with HLA-DR4 (17) . In an earlier study, the association of haplotypes that contained these alleles to type I diabetes was shown, and the authors concluded that these associations were due to several susceptibility loci that were linked to specific HLA alleles (18) .
In the present study, we analyzed MHC markers (HLA-A, B, C, DR, BF, C2, C4A, C4B, and GLO) in families of type I diabetic patients, and defined extended haplotypes with specific sets of alleles of HLA, complement, and GLO loci. The extended haplotypes occur with different frequencies among patient and normal chromosomes, and allow the differentiation of more specific associations of certain extended haplotypes with susceptibility genes of type I diabetes than is possible for individual alleles (e.g., HLA-DR3, DR4, or BF*FJ). (14) . Table I shows that the frequencies ofrepresentative DR and GLO alleles in these 448 normal haplotypes do not differ significantly from the 74 normal haplotypes from diabetic families.
Use ofthe normal haplotypes from the families under study obviated the potential ethnic variations between random normal and random diabetic haplotypes. To determine whether this population of normal haplotypes in families with patients with type I diabetes was similar to our larger population ofnormal Caucasian chromosomes (14) , for which the ethnicity was not carefully determined but which was approximately similar to that of the study population, the frequencies of HLA-DR Figure 1 . A hypothetical pedigree of a family ascertained for BF Fl that demonstrates how haplotypes were classified as normal or "diabetic". Two children (IDDM) have type I diabetes. Their genotypes are B18, DR3, FIC30, GL02/B8, DR3, SCO0, GLO2 and B15, DR4, SC33, GLO2/B18, DR3, FlC30, GLO2. Since the family was ascertained for BF Fl, the B18, DR3, FIC30, GLO2 chromosome was excluded from the "diabetic" group. The two chromosomes, B8, DR3, SCO1, GLO2 and B15, DR4, SC33, GLO2 were classified as "diabetic", and the chromosome B18, DR2, SC3 1, GLOI was called normal. (Table I ) and common extended haplotypes were compared by the x2 test. There were no significant differences (all P > 0.05).
BF, C2, and C4 typing. Fresh or freshly frozen (at -70°C) serum or EDTA plasma samples were subjected to agarose gel electrophoresis at pH 8.6 and immunofixation with goat antiserum to human factor B (Atlantic Antibodies, Scarborough, ME) for BF typing (20) . For C2 types, the same samples were analyzed by isoelectric focusing in polyacrylamide gels (21) and then an overlay of agarose gel that contained antibody-sensitized sheep erythrocytes and human serum diluted 1:90 in isotonic Veronal-buffered saline, pH 7.4, which contained 0.1% gelatin, 10-3 M Mg", and 1.5 x 101 M Ca". Portions of the same samples were treated with Clostridium perfringens neuraminidase (Sigma Chemical Co., St. Louis, MO) at 10 U/ml for 15 h at 4°C before agarose gel electrophoresis at pH 8.6 and crossed immunoelectrophoresis for detection of half-null C4 haplotypes (22) , or to agarose gel electrophoresis at pH 8.6, and immunofixation with anti-C4 (Atlantic Antibodies), for detection of structural variants of C4A and C4B (23) . Complotypes are given in arbitrary order as BF, C2, C4A, and C4B types run together, with "0" for QO (null) alleles (12 (24) . HLA-A, B, C, and DR typing. Routine typing was performed using a modification of the National Institutes of Health Standard Microlymphocytotoxicity Test procedure. 140 antisera were used for defining 19 A-locus, 28 B-locus, and 6 C-locus antigens. Routine HLA-DR typing Notes on C4 nomenclature
Confusion has arisen concerning the name of the HLA-B5-associated C4B allele. In this paper it is denoted as C4B*3, as suggested by an international committee (26) . This committee has defined the allele associated with HLA-BW47 as C4B*31 (26) . Others have denoted the latter allele as C4B*3 and the one associated with HLA-B15 as C4B*2.9 (27, 28). The original paper, which noted the association of this allele with HLA-B15 in diabetes called it C4B*4 (29). We have previously referred to the HLA-B15-associated C4B allele on normal chromosomes as C4B*3 in our discussion ofthis extended haplotype (14) . The current accepted designation for the HLA-B15-associated C4B allele is C4B*3.
Results
From the study of 18 randomly ascertained families with diabetic patients, 39 haplotypes occurred in patients and were defined as random type I diabetes mellitus haplotypes. An additional 22 random diabetic haplotypes were obtained from 20 families that were ascertained for BF Fl or BF SI. From the remaining haplotypes in these families (i.e., those not occurring in known diabetic patients) and from the nonpatient haplotypes that occurred in families selected for BF S1 or BF F1, 74 normal haplotypes were also defined. Fig. 2 shows an analysis ofthese random diabetic and normal haplotypes that were classified according to DR types. The upper portion of the Fig. 2 A shows the absolute frequencies of haplotypes of different DR types among the diabetic and two kinds of normal chromosomes. Diabetic haplotypes are at the left, and normal haplotypes from diabetic families are in the center, and haplotypes from overall control families are to the right of each set of bars in Fig. 2 . Nonextended haplotypes are shown in the crosshatched areas, and known extended haplotypes are shown within each bar. There were no significant differences in the frequencies ofextended haplotypes among diabetic normals and all normals, and this excludes population stratification or other trivial mechanisms as causes for the findings in diabetics.
The well known increase in HLA-DR3 and DR4 and the decrease in DR2 among diabetic patients' chromosomes is evident. The pared with normal ( Fig. 2 A) (15, 16) . This is also consistent with the finding that HLA-D ,B-chain restriction fragment length polymorphisms in genomic DNA differ between HLA-DR-identical healthy and insulindependent diabetic individuals (30).
A corollary of a model that assigns a simple primary role for the HLA-DR alleles is that the proportions of individual extended haplotypes would be the same among HL,A-DR3 and DR4 haplotypes in patient and normal chromosomes. Our data show that this is not the case. The most striking deviation is the unexpected finding that the GLO1/GLO2 ratio among [HLA-B8, DR3, SCOI] haplotypes in type I diabetes as compared with normal chromosomes is reversed. Thus, two very similar haplotypes, both carrying the known diabetic markers HLA-B8 and DR3, which were distinguished only by their GLO types, differ radically in conferring susceptibility to diabetes. GLO per se is, of course, not a marker for type I diabetes mellitus, as shown in this and previous studies (1 1, 31) . Kirk et (35) , is rare. The disease gene has a frequency of <1%, although it is fully penetrant, and the extended haplotype marking it is rare (<0.003) in the normal population.
We have previously suggested that some extended haplotypes mark murine t-like analogues in man (36) . Wild mouse populations frequently carry mutant genes on chromosomes 17 (the chromosome that bears the murine MHC) called the T/t complex. These mutants are lethal in the homozygote and are usually transmitted by the male to almost all of his offspring. The T/t complex, which includes the MHC, is associated with crossover suppression in meioses which involve mutant and wild chromosomes. Crossover suppression and male transmission bias, if they occur in human analogues of t-mutants, would produce extended haplotypes. We suggested that t-analogues would function as genetic sinks and collect a variety of deleterious mutations, including susceptibility genes to various disorders, which include type I diabetes. We also presented evidence that the [HLA-B8, DR3, SCOI, GL02] haplotype has at least one feature of murine t-mutants and shows a male transmission bias of >0.8 (14, 37 
